Insulet Corporation $PODD Shares Sold by Sei Investments Co.

Sei Investments Co. lowered its stake in shares of Insulet Corporation (NASDAQ:PODD) by 13.4% during the first quarter, Holdings Channel reports. The institutional investor owned 156,602 shares of the medical instruments supplier’s stock after selling 24,238 shares during the period. Sei Investments Co.’s holdings in Insulet were worth $32,862,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Walleye Capital LLC boosted its stake in shares of Insulet by 318.4% during the 1st quarter. Walleye Capital LLC now owns 4,886 shares of the medical instruments supplier’s stock worth $1,025,000 after acquiring an additional 7,123 shares in the last quarter. State of Wyoming increased its stake in Insulet by 34.6% in the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after purchasing an additional 73 shares in the last quarter. Icon Advisers Inc. Co. purchased a new position in Insulet in the 1st quarter valued at approximately $1,259,000. PNC Financial Services Group Inc. raised its holdings in Insulet by 2.1% during the first quarter. PNC Financial Services Group Inc. now owns 13,406 shares of the medical instruments supplier’s stock worth $2,813,000 after purchasing an additional 274 shares during the last quarter. Finally, Earned Wealth Advisors LLC acquired a new position in Insulet during the first quarter worth $236,000.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.36% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have weighed in on PODD shares. BTIG Research lowered their target price on Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a report on Tuesday, May 26th. Stifel Nicolaus cut their price target on Insulet from $250.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Wall Street Zen lowered shares of Insulet from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 27th. Canaccord Genuity Group lowered their price objective on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Finally, Bank of America dropped their target price on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a report on Monday, May 18th. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $235.25.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Multiple firms—including Rosen, Bronstein Gewirtz & Grossman, Levi & Korsinsky, Faruqi & Faruqi, and Bleichmar Fonti & Auld—issued substantially similar notices. The repeated releases primarily seek to attract investors to the existing litigation rather than announce separate new legal actions. Rosen investor notice
• Neutral Sentiment: The proposed class periods vary by notice, generally covering purchases from February 21 or May 21, 2025, through May 26, 2026. Investors who purchased during the applicable period may petition the court by August 31, 2026, to serve as lead plaintiff, with firms stating that representation is offered on a contingency-fee basis. Levi and Korsinsky notice
• Negative Sentiment: The lawsuit creates a potential financial liability, management distraction, and ongoing uncertainty for Insulet. Continued legal notices may weigh on investor sentiment, particularly because the allegations relate to conduct that plaintiffs say contributed to the earlier stock selloff. Bleichmar Fonti and Auld lawsuit notice

Insulet Price Performance

PODD stock opened at $165.00 on Tuesday. The stock’s 50 day moving average price is $154.34 and its 200 day moving average price is $201.13. The firm has a market cap of $11.43 billion, a P/E ratio of 38.37, a PEG ratio of 1.14 and a beta of 1.11. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter last year, the business posted $1.02 earnings per share. Insulet’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, sell-side analysts expect that Insulet Corporation will post 6.45 earnings per share for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.